CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The purpose of this study is to find out the effect that CFI-400945 and durvalumab have on breast cancer....
Phase 2
Toronto, Ontario, Canada and 4 other locations
This study will assess the efficacy and safety of Niraparib in participants with either tumor mutation in the BRCA gene (tBRCAmut) HER2- breast...
Phase 3
Toronto, Ontario, Canada and 199 other locations
This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC...
Phase 3
Toronto, Ontario, Canada and 228 other locations
previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors...
Phase 3
Toronto, Canada and 508 other locations
after induction with first-line chemotherapy plus pembrolizumab in triple negative breast cancer (TNBC). The prim...
Phase 2
Toronto, Ontario, Canada and 121 other locations
with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors...
Phase 3
Toronto, Canada and 508 other locations
vs placebo as adjuvant therapy in participants who have triple negative breast cancer (TNBC).After a screening ph...
Phase 3
Toronto, Ontario, Canada and 192 other locations
with stage I to III TNBC with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvan...
Phase 3
Toronto, Ontario, Canada and 360 other locations
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without du...
Phase 3
Toronto, Ontario, Canada and 285 other locations
monotherapy versus olaparib in combination with an inhibitor of WEE1 (adavosertib \[AZD1775\]) in second or third line setting in patients with Triple...
Phase 2
Toronto, Ontario, Canada and 140 other locations
Clinical trials
Research sites
Resources
Legal